Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers

SIMPLE SUMMARY: Larotrectinib and entrectinib have never been directly compared in a clinical trial for the treatment of TRK fusion-positive cancer, so a comparison must use separate data from each drug’s trials. This study used established statistical methods to balance the patient populations acro...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Foncillas, Jesus, Bokemeyer, Carsten, Italiano, Antoine, Keating, Karen, Paracha, Noman, Fellous, Marc, Marian, Marisca, Fillbrunn, Mirko, Gao, Wei, Ayyagari, Rajeev, Lassen, Ulrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997457/
https://www.ncbi.nlm.nih.gov/pubmed/35406565
http://dx.doi.org/10.3390/cancers14071793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997457/
https://www.ncbi.nlm.nih.gov/pubmed/35406565
http://dx.doi.org/10.3390/cancers14071793

Ejemplares similares